Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.
Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.


RARE DISEASE
Retinitis pigmentosa
Retinitis pigmentosa
Retinitis pigmentosa
Drug discovery
98
drugs
With orphan designations
Rare ophthalmic disorders
Retinitis pigmentosa
Overview
Retinitis pigmentosa (RP) is a group of inherited retinal dystrophies characterized by progressive degeneration of rod and cone photoreceptors, leading to night blindness, peripheral vision loss, and eventual central vision impairment. Caused by mutations in over 60 genes, RP typically manifests in childhood/adolescence and progresses variably. No cure exists, but therapeutic strategies aim to slow progression (e.g., vitamin A supplementation, gene therapy for specific mutations) and manage complications (e.g., cataracts, macular edema) [1][2][6][11].
Burden
Leading cause of inherited blindness; 5–7% of new blindness cases in Western countries [4][7].
Legal blindness in ~40% by age 40; severe quality-of-life decline, unemployment, and caregiver strain [4][7][16].
Annual U.S. economic burden exceeds $1 billion, including direct healthcare and indirect productivity losses [4][16].
Therapies
Gene therapy: FDA-approved voretigene neparvovec (RPE65 mutations) [13][17]; experimental therapies (e.g., QR-421a for USH2A) in trials [13].
Supportive care: Vitamin A palmitate (15,000 IU/day) to slow progression; avoid high-dose vitamin E [1][11][18].
Low-vision aids: Retinal prostheses, orientation training, and adaptive technologies [6][11][15].
Categories: rare genetic diseases, rare neurological diseases, rare ophthalmic disorders
Research Papers
3,422 drug discovery papers about Retinitis pigmentosa, with 2 first-in-class and 53 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
3,422 drug discovery papers about Retinitis pigmentosa, with 2 first-in-class and 53 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
categories:
Small molecules
small molecules
2026-09-26 | Dual Targeting of Galanin Receptor 3 Signaling and Redox Homeostasis Enhances Photoreceptor Survival in Retinas of rd10 Mice.
Retinitis pigmentosa (RP) is a genetically heterogeneous group of inherited retinal degenerative disorders characterized by progressive photoreceptor loss and vision impairment, for which broadly applicable mutation-independent therapies remain limited. To examine the therapeutic potential of combined galanin receptor 3 (GALR3) inhibition and antioxidant therapy in a mutation-independent context, we utilized the rd10 mouse model of RP. We first evaluated the effects of individual treatments with the GALR3 antagonist SNAP-37889 and the antioxidant quercetin, followed by a combined treatment regimen to determine whether simultaneous targeting of neuroinflammatory and oxidative stress pathways provides enhanced retinal protection. Treatment efficacy was assessed using functional and morphological analyses, including electroretinography (ERG) to measure retinal function, optical coherence tomography (OCT) to evaluate retinal structure in vivo, and histological and immunohistochemical analyses to quantify photoreceptor survival and markers of retinal oxidative stress and inflammation. Although the expression levels of individual inflammatory and oxidative stress markers did not consistently exhibit additive responses, the combined treatment produced greater photoreceptor survival and preservation of photopic retinal function than either monotherapy alone. These findings support the hypothesis that simultaneous modulation of oxidative stress and neuroinflammation provides greater neuroprotective benefits, establish a foundation for the development of mutation-independent therapeutic strategies for RP, and identify GALR3 as a promising therapeutic target.
2026-09-16 | Microbiota-mitochondria axis in neurodegenerative disorders and retinal dysfunction: mechanisms and emerging therapeutic opportunities.
The gut microbiota crucial role in maintaining host metabolism, immune homeostasis, intestinal integrity, and mitochondrial function. Emerging evidence suggests that dysregulation of the microbiota-mitochondria axis represents one of the key mechanisms linking gut dysbiosis to the development of neurodegenerative and ocular diseases. The dysbiosis causes disruptions in mitochondrial physiology due to lower levels of short-chain fatty acids, increased intestinal permeability, endotoxemia, oxidative stress, and inflammation. These mechanisms contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, age-related macular degeneration, diabetic retinopathy, retinitis pigmentosa, and central serous chorioretinopathy. Environmental factors such as unhealthy dietary patterns, excessive antibiotic use, and prolonged exposure to artificial blue light may exacerbate dysbiosis and further disrupt mitochondrial homeostasis, thereby contributing to disease progression. We also elaborated the emerging therapeutic strategies targeting both the gut microbiota and mitochondrial function, including next-generation probiotics, postbiotics, dietary interventions, mitochondria-targeted antioxidants, NAD+ precursors, and precision medicine approaches. Collectively, current evidence represents the microbiota-mitochondria axis as a one of the promising mechanistic and therapeutic targets for neurodegenerative and ocular diseases. However, most therapeutic evidence discussed in this review is derived from preclinical studies, with relatively limited clinical validation. Future well-designed longitudinal studies and randomized clinical trials are essential to establish efficacy, safety, and translational applicability in humans.
2026-09-15 | PGC-1α and PPARs cooperatively mediate photoreceptor neuroprotection in rd1 mouse inherited retinal degeneration.
Retinitis pigmentosa (RP) is a group of inherited diseases characterized by primary rod photoreceptor dysfunction and progressive cone cell death. Due to their very high energy demand, the degeneration of photoreceptors may be linked to insufficient energy supply or metabolic imbalance. Critical transcription factors that regulate metabolism, such as peroxisome proliferator-activated receptors (PPARs) and PPAR gamma coactivator 1α (PGC-1α), have been found to play important roles in neurodegenerative diseases, but their potential roles in RP have yet not been elucidated. Here, organotypic retinal explant cultures derived from retinal degeneration 1 (rd1) mice were used to investigate the effects of PPARα, PPARγ, PPARβ/δ agonists, as well as PGC-1α activation and inhibition. Photoreceptor death was quantified using the TUNEL assay, while in situ activity assays were used to monitor effects of PPARs and PGC-1α on poly (ADP-ribose) polymerase (PARP) and calpain activity. Generation of poly (ADP-ribose) (PAR) and activation of calpain-1 and calpain-2 were evaluated by immunostaining. PGC-1α/PPAR-associated transcriptional changes were assessed by RT-qPCR. We found that PPARβ/δ agonists had limited effects, while treatment targeting PPARα, PPARγ, and PGC-1α significantly reduced photoreceptor death and PARP activity in rd1 retina. RT-qPCR analysis in treated rd1 retina confirmed upregulation of genes downstream of PGC-1α/PPAR signaling. Stimulation of the histone deacetylase sirtuin-1, an upstream regulator of PGC-1α, had no beneficial effect on photoreceptor viability unless combined with PARP inhibition. Furthermore, PPARγ and PGC-1α effectively suppressed overall calpain activity and overactivation of calpain-2, alleviating photoreceptor degeneration caused by Ca2+ imbalance. In summary, our data support the concept of a PARP-sirtuin-1-PGC-1α-PPAR-PARP feedback control that connects defective energy metabolism to photoreceptor degeneration. Specifically, our findings suggest that PPARα, PPARγ, and PGC-1α cooperate to preserve photoreceptor viability, highlighting PPAR-signaling as a promising target for future therapeutic interventions.
2026-09-11 | herapeutic Possibilities of N-acetylcysteine in Retinitis Pigmentosa: A Scoping Review
This scoping review aims to analyze the extent of evidence regarding ophthalmological manifestations associated with cluster headache, including clinical findings, potential pathophysiological mechanisms, and their relevance to clinical recognition and the differential diagnosis of the disease. The guiding question was structured using the PCC mnemonic: "What is the evidence regarding the therapeutic use of N-acetylcysteine in retinitis pigmentosa?". Additionally, four specific questions were defined as key elements. The literature search will be conducted using the PubMed, BVS, and SciELO databases. Studies resulting from the searches will be exported to Rayyan.ai software and selected in two phases based on pre-established criteria. Stage I will consist of screening articles by title and abstract, while Stage II will involve a full-text review of the selected articles. A qualitative synthesis will be prepared based on data extracted from the selected studies. The extracted data will also be summarized in a descriptive table containing concise answers to all specific questions.
2026-08-28 | Novel insights of minocycline as a neurovascular protective agent in retinitis pigmentosa.
Retinitis pigmentosa (RP) is characterised by progressive photoreceptor degeneration accompanied by vascular abnormalities. We have previously demonstrated that minocycline exhibits therapeutic potential in RP. This trial aimed to evaluate its neurovascular protective effects. Patients with RP were enrolled and administered 100 mg of minocycline once daily for 12 months. A total of 32 eyes from 16 participants were included. The primary outcomes were changes in retinal and choroidal vasculature, including vessel density, lacunarity, foveal avascular zone (FAZ) area, fluorescein angiography (FA) score and subfoveal choroidal thickness (SFCT). The secondary outcomes included changes in photoreceptor structure and function, including ellipsoid zone width, best-corrected visual acuity (BCVA), mean macular sensitivity, mean deviation (MD) and error score. Adverse events were recorded. Additionally, Rd1 mice were used to further investigate the vascular effects of minocycline. After 12-month minocycline treatment, RP patients exhibited increased vessel density in both the retinal superficial capillary plexus (SCP) and retinal deep capillary plexus (DCP), accompanied by reduced FAZ area and decreased lacunarity in the SCP and DCP. FA score and SFCT remained stable, as did all secondary outcomes. A total of 24 adverse events were reported in 8 patients, and all resolved spontaneously without additional intervention. Additional experiments in Rd1 mice demonstrated improved retinal vascular abnormalities and preserved blood-retinal barrier integrity, accompanied by upregulated expression of tight junction proteins. Oral 100 mg minocycline once daily for 12 months was beneficial to protect vascular integrity and stabilise photoreceptor structure and function with good tolerability.
proteins
2026-09-23 | Photobiology in ophthalmology: from evolutionary adaptation to translational therapeutics.
Life has evolved under continuous exposure to solar light, and the emergence of the eye during the Cambrian period is thought to have accelerated biological diversification. Beyond vision, light acts as a biological regulator of metabolism and tissue organization. To elucidate ocular disease mechanisms and develop new therapies, we have investigated how light is sensed by the eye and coupled to physiological and pathological responses. This review reexamines the eye as a photoreceptive organ and summarizes recent advances showing how light input governs retinal metabolism, refractive development, and visual restoration. First, we describe how retinal light reception is linked to oxygen-dependent metabolic control. As one of the most oxygen-demanding tissues, the retina relies on hypoxia-inducible factor (HIF) signaling to coordinate angiogenesis, mitochondrial metabolism, fibrosis, and neuronal survival. Beyond pathological neovascularization, disrupted light-metabolic coupling contributes to neurodegeneration and subretinal scarring. Screening of natural compounds identified HIF regulators with therapeutic efficacy, and optical approaches were developed to detect hypoxia-induced intraocular cytokines noninvasively. Second, we show that environmental light regulates ocular growth in ways beyond image formation. Violet light activates nonvisual photoreception via OPN5-expressing retinal ganglion cells, engaging an OPN5-EGR1 pathway that preserves choroidal thickness and suppresses axial elongation through coordinated retina-brain-choroid-sclera interactions. Third, we demonstrate that light itself becomes therapeutic through optogenetic visual restoration. Chimeric rhodopsins confer high-sensitivity light responsiveness to surviving inner retinal neurons and have recently entered first-in-human clinical evaluation for advanced retinitis pigmentosa. These findings establish photobiology as a unifying framework for translational ophthalmology.
2026-08-15 | Phase I/IIa Study of an Intravitreal Optogenetic Therapy (AGN-151597) in Patients with Advanced Retinitis Pigmentosa.
Retinitis pigmentosa is an incurable, inherited retinal disease that causes vision loss and blindness. We evaluated the safety and preliminary efficacy of AGN-151597, a mutation-independent optogenetic therapy encoding channelrhodopsin-2, in patients with advanced retinitis pigmentosa. First-in-human, phase I/IIa, open-label, dose-escalation study (1 study eye/participant). Participants had advanced retinitis pigmentosa with severely impaired visual function. Participants received an intravitreal injection of low-dose (4.3 × 1010 vg/eye; n = 3), mid-dose (1.4 × 1011 vg/eye; n = 4), or high-dose (4.3 × 1011vg/eye; n = 7) AGN-151597 in the study eye. The study duration was 24 months followed by a 3-year safety extension. The primary safety endpoint was safety at 6 months as assessed by intraocular pressure and changes in visual acuity, full-field sensitivity, ambulation, and visual anatomical parameters. Efficacy measures included changes in visual acuity, full-field stimulus threshold (FST), ambulation, object detection/discrimination, visual evoked potentials, electroretinography, and visual function-related quality of life (questionnaire). Fourteen patients (median age 62 years) were enrolled. AGN-151597 treatment resulted in no clinically significant changes in ocular safety assessments. Most treatment-emergent adverse events (TEAEs) were ocular; none were severe. The most common treatment-related TEAE was transient increased intraocular pressure (n = 3). No clinically significant efficacy was observed. Full-field stimulus threshold measurements in both eyes showed good agreement between the screening and baseline visits, with coefficients of repeatability of 6.2 for blue light, 2.7 for red light, and 5.3 for white light. Overall mean FST in study eyes at baseline was -13.5 dB for blue light, -1.0 dB for red light, and -5.2 dB for white light. Participants' mean FST changed similarly in both eyes over 24 months for each light stimulus. There was no evidence of AGN-151597 efficacy in slowing vision decline in patients with advanced retinitis pigmentosa. However, the absence of safety concerns over 5 years after intravitreal administration of an adeno-associated virus type 2 vector-delivered genetic medicine is encouraging and supports further gene therapy endeavors to enhance visual function in this devastating retinal disease. Full-field stimulus threshold is a reliable test in patients with poor vision. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
2026-08-04 | WDR34 Deficiency Disrupts Retrograde Intraflagellar Transport and Induces Unfolded Protein Response-Driven Inflammation and Retinal Degeneration.
Retinitis pigmentosa (RP) is a hereditary retinal disease characterized by progressive photoreceptor cell (PRC) degeneration. WD repeat domain 34 (WDR34), an intermediate chain of dynein-2, is essential for retrograde intraflagellar transport (IFT). However, the mechanisms by which WDR34 deficiency causes retinal degeneration remain unclear. This study aims to investigate the impact of WDR34 deficiency on retrograde IFT and its contribution to retinal degeneration. WDR34 deficiency was modeled in vivo via subretinal injection of adeno-associated virus-shRNA-WDR34 and in vitro by CRISPR/Cas9-mediated knockout in 661W cells. Retinal degeneration and IFT defects were assessed by histologic, functional, and ultrastructural analyses. Proteomic analysis followed by in vivo validation was used to investigate the molecular mechanism underlying WDR34-deficient retinal degeneration. WDR34 knockdown induced progressive retinal degeneration characterized by PRC apoptosis, gradual outer nuclear layer thinning, reduced electroretinography responses, and outer segment shortening. WDR34 deficiency impaired retrograde IFT and caused rhodopsin and opsin mislocalization. These alterations induced endoplasmic reticulum stress and unfolded protein response (UPR) activation, activating the IRE1α/TRAF2/NF-κB signaling pathway, ultimately contributing to retinal inflammation and degeneration. WDR34 is crucial for maintaining retrograde IFT in PRCs. WDR34 deficiency disrupts outer segment maintenance and triggers UPR-mediated inflammatory responses and apoptosis, ultimately leading to retinal degeneration. This study reveals a novel mechanistic link among WDR34, retrograde IFT, ciliopathies, and retinal degeneration, providing potential therapeutic insights for ciliopathy-associated RP.
2026-07-27 | The Drosophila CEBPG homolog Irbp18 partners with crc (ATF4) to mediate the integrated stress response in degenerative disease models.
The integrated stress response (ISR) coordinates cellular adaptation to diverse stress conditions. In Drosophila, two bZIP transcription factors, Xrp1 and crc (ATF4 homolog), are induced during ISR. Crc protein can dimerize with two CEBP factors in vitro, but the in vivo relevance of those interactions remained unknown. Here, we report that the CEBPG homolog, Irbp18, is an essential partner of crc during ISR. Specifically, Irbp18 is broadly required for the transcriptional induction of ISR target genes in the photoreceptors of ninaEG69D, a Drosophila model of retinitis pigmentosa. Moreover, CUT&RUN analysis indicates that Irbp18 loss reduces or abolishes crc binding to target DNAs in photoreceptors and impairs crc's ability to induce target transcripts upon overexpression. Functionally, Irbp18 loss causes retinal degeneration and suppresses ISR signaling in parkin mutants, a model of Parkinson's disease. Together, these findings identify Irbp18 as a cofactor for crc, impacting pathological outcomes in Drosophila models of degeneration.
2026-05-15 | Chromophore-loaded CRALBP mutant proteins restore rod function in chromophore-deficient mice.
Visual function depends critically on the supply of visual chromophore, 11-cis-retinal, to the photoreceptor cells in the retina. Chromophore deficiency due to aging or mutations affecting its delivery and recycling in the eye by the retinal pigment epithelium (RPE) and the Müller cells cause a wide range of visual disorders. The cellular retinaldehyde-binding protein (CRALBP), expressed in both compartments, crucially aids in accelerating the recycling of visual chromophore. Here, we explored the potential of chromophore-loaded CRALBP in restoring vision in chromophore-deficient mice. We tested wild-type human CRALBP and its redox-sensitive A212C:T250C mutant, both pre-loaded with 9-cis-retinal, for their efficacy in delivering chromophore to the retina and restoring rod photoreceptor function in RPE65-deficient mice that cannot produce visual chromophore. We observed robust restoration of rod function both in the isolated retina treated with chromophore-loaded CRALBP and in vivo after a single intravitreal injection of wild-type or mutant CRALBP proteins. Notably, the recovery of rod visual function after exposure to bright light that photoactivated most of the visual pigment was greatly accelerated in CRALBP-treated RPE65-knockout mice compared to wild-type control mice. Together, our results highlight the therapeutic potential of CRALBP complexes in efficiently delivering visual chromophore to retinal rod photoreceptors.
gene therapies
2026-09-22 | A novel PRPF31 variant associated with autosomal dominant retinitis pigmentosa in Japanese families.
PRPF31-associated inherited retinal dystrophy is an autosomal dominant form of retinitis pigmentosa (RP), typically caused by haploinsufficiency. Although affected individuals generally exhibit early-onset nyctalopia and progressive visual field loss, the clinical and genetic characteristics associated with individual PRPF31 variants remain incompletely defined, particularly for variants initially classified as variants of uncertain significance (VUS). We investigated five unrelated families carrying the same heterozygous PRPF31 variant, c.613_615del (p.Tyr205del), which was previously classified as a VUS. Clinical and genetic data were systematically collected from 15 individuals carrying the variant. Segregation patterns and clinical findings were assessed in relation to the established disease mechanism. In addition, cross-sectional clinical characteristics were analyzed in 35 individuals with PRPF31-associated RP to characterize the disease phenotype and progression. The accumulated familial and phenotypic evidence provided additional support for the pathogenicity of p. Tyr205del, enabling its reclassification as a likely pathogenic variant. Analysis of 35 affected individuals showed that PRPF31-associated RP follows the typical progression pattern of classical RP, with rod-predominant degeneration followed by progressive deterioration of central visual function. Systematic accumulation of clinical and familial data across multiple cases can provide important evidence for variant interpretation, particularly for rare PRPF31 variants initially classified as VUS. Integrating genetic, segregation, and phenotypic information may improve diagnostic accuracy and facilitate the identification of patients who may benefit from future PRPF31-targeted therapies.
2026-09-15 | InsightRP2-An Interdisciplinary Approach Toward Therapy Development in RP2-Associated Retinopathy.
Advancing the development of specific gene therapies for rare genetic eye disorders is a major challenge in modern translational vision research. It requires integrated clinical, molecular, mechanistic, and regulatory expertise, yet these aspects are often addressed in isolation. Combining complementary skills, knowledge, and expertise within an integrated, highly interactive research framework has the capacity to drive and advance therapeutic development. Moreover, early-stage involvement of patients and targeted clinical observation, alongside molecular and therapeutic research, potentially enable clinical trial readiness and support the translation of preclinical therapeutic innovations into clinical care. In this Perspective article, we present the InsightRP2 framework, an integrated translational strategy that incorporates clinical data, artificial intelligence-supported imaging analysis, experimental disease modeling, and adeno-associated virus design with the aim to facilitate the development of a targeted gene therapy for RP2-associated retinitis pigmentosa.
2026-09-14 | Progress in gene therapy for RPGR-associated X-linked retinitis pigmentosa.
X-linked retinitis pigmentosa (XLRP) caused by pathogenic variants in RPGR is among the most severe inherited retinal dystrophies, with childhood-onset nyctalopia followed by progressive visual-field constriction and central visual loss. The purine-rich ORF15 terminal exon has driven sustained development of adeno-associated virus-mediated gene supplementation. This review summarizes the molecular biology of RPGR, the challenge of stabilizing the ORF15 transgene, the principal clinical programs, and endpoint selection in pivotal trials. Clinical development has followed two transgene strategies: codon optimization preserving full-length RPGRORF15, or a construct containing a 126-amino-acid deletion removing approximately 36% of the Glu-Gly-rich region and 6 of 11 identified glutamylation consensus motifs. Beyond transgene design, appropriate endpoint selection is critical to demonstrating therapeutic efficacy in RPGR-XLRP. The multi-luminance mobility test was developed for RPE65-associated retinal dystrophy, where visual-cycle restoration can rapidly improve night vision, and may be less suited to slowly progressive RPGR-XLRP. Microperimetry can detect localized changes in retinal sensitivity but requires careful standardization and repeated baseline testing to minimize learning effects. Low-luminance visual acuity (LLVA) represents an attractive primary functional endpoint for: it is simple, standardized and clinically meaningful, while challenging central visual function under conditions in which RPGR-XLRP patients may be impaired despite preserved conventional acuity. Importantly, XIRIUS demonstrated treatment-related improvements in LLVA and mean microperimetry sensitivity, supporting the responsiveness of both measures to therapeutic intervention in RPGR-XLRP. LLVA and microperimetry are well suited to primary efficacy assessment in RPGR-XLRP, with endpoint selection guided by disease stage and the anticipated treatment effect and supported by complementary structural biomarkers.
2026-09-09 | Bionic vision technologies: progress and perspectives on retinal prostheses and optogenetics for the treatment of advanced retinal degeneration.
Advanced degenerative retinal diseases [e.g., retinitis pigmentosa (RP) and age-related macular degeneration (AMD)] are characterized by irreversible photoreceptor loss, and conventional interventions rarely prevent progression to profound vision loss at advanced stages. Retinal prostheses and optogenetic therapies are two leading bionic strategies to bypass absent photoreceptors, yet both are limited by a shared "encoding-biointerface" bottleneck: converting external scenes into interpretable neural activity in surviving retinal circuits with adequate selectivity, safety margins, and long-term stability. This review critically compares the two approaches in spatial resolution, neural adaptation, and biosafety, while explicitly distinguishing clinical evidence from preclinical and proof-of-concept studies. Retinal prostheses provide near-term light perception and limited form vision but are constrained by current spread, non-selective pathway/axon recruitment, interface reactions, and cortical decoding burden. Optogenetic restoration offers cell-type-biased reactivation and potentially more physiological processing, but currently remains coupled to external light-delivery hardware and is limited by scattering, heterogeneous transduction, safety-limited irradiance, restricted dynamic range, and adeno-associated virus (AAV)-related inflammatory risk. We highlight emerging integrative directions, including opto-electronic hybrid interfaces, adaptive encoding, broadband subretinal nanomaterial-based photovoltaic nanoprostheses, and experimental acoustic modalities (e.g., focused ultrasound and sonogenetics), alongside ethical and accessibility considerations for translation.
2026-09-08 | Generation of isogenic gene-corrected cell lines from a USH2A-RP patient-derived iPS cell line.
Comparative studies using induced pluripotent stem cells (iPSCs) from patients with those from healthy individuals as controls are flawed by genetic background contribution to disease phenotype. Here, we used precise gene editing to generate gene-corrected isogenic control lines for a single pathogenic variant in the USH2A gene (c.2276G > T) associated with retinitis pigmentosa (RP). Both homozygously and heterozygously corrected cell lines were successfully generated. These cell lines will serve to unravel RP phenotype differences specific to the USH2A mutation upon their conversion into disease relevant cell types.
cell therapies
2026-09-25 | Stem Cell-Based Strategies for Retinal Cell Restoration.
Retinal degenerative diseases, including age-related macular degeneration, retinitis pigmentosa, diabetic retinopathy, and inherited retinal dystrophies, are among the leading causes of irreversible vision loss and blindness worldwide. Current treatments primarily slow disease progression and are unable to restore lost retinal cells or visual function, highlighting the need for regenerative therapeutic strategies. Stem cell-based therapies have emerged as a promising approach for retinal repair through multiple mechanisms, including retinal cell replacement, stimulation of endogenous regeneration, cellular reprogramming, immunomodulation, and paracrine signaling. This narrative review provides a comprehensive overview of the major stem cell sources investigated for retinal regeneration. In addition, the roles of extracellular vesicles and retinal organoids as emerging therapeutic platforms are discussed. Particular emphasis is placed on comparing the biological rationale, therapeutic potential, current preclinical and clinical evidence, and translational readiness of each approach. Despite encouraging progress, several challenges continue to limit routine clinical application, including poor survival and integration of transplanted cells, immune rejection, tumorigenicity, genomic instability, variability in differentiation efficiency, manufacturing standardization, and long-term safety. Continued advances in stem cell biology, tissue engineering, gene editing, and clinical trial design are expected to accelerate the development of safe and effective regenerative therapies for retinal diseases.
2026-07-09 | Photoreceptor-targeted engineered exosomes encapsulating black phosphorus quantum dots for alleviating photoreceptor degeneration.
Photoreceptor degeneration is a major cause of irreversible visual impairment worldwide, most notably in retinitis pigmentosa (RP). Here, we developed a dual-targeted therapeutic nanoplatform by loading black phosphorus quantum dots (BPQDs) into human dental pulp mesenchymal stem cell-derived exosomes (hDPSC-Exos) and surface-modifying with cell-penetrating peptide transactivated transcription (TAT) and photoreceptor-specific peptide MH42, namely TAT/MH42-engineered black phosphorus quantum dot-loaded exosomes (M/T-BPQD@Exos). M/T-BPQD@Exos showed typical exosomal morphology and good uniformity. In vitro, M/T-BPQD@Exos effectively protected 661 W photoreceptor cells against N-methyl-N-nitrosourea (MNU) injury. In vivo, M/T-BPQD@Exos specifically accumulated in the outer nuclear layer (ONL) and significantly preserved retinal structure and visual function in MNU-induced photoreceptor degeneration rats. Biosafety assessment confirmed no obvious systemic toxicity and inflammation. Mechanistically, M/T-BPQD@Exos alleviated calcium overload, maintained mitochondrial integrity, and suppressed mitochondrial apoptosis by regulating Bcl-2, Bax, and cleaved caspase-3. This study provides a safe and precise strategy for photoreceptor protection in retinal degenerative diseases.
2026-05-31 | Stem cell therapy in retinal disease.
Stem cell therapy presents a new solution to cure degenerative diseases of the retina, which normally have limited ability to regenerate after injury. Stem cells are cells capable of self-renewal and differentiation into more specialized cells, and can be derived from both embryonic and adult sources. This definition encompasses a heterogeneous group of cells possessing varied potency and characteristics. Current attempts in applying stem cell technology to the retina have primarily focused on regenerating the retinal pigment epithelium (RPE) and light-sensing photoreceptor cells. They have not only shown the ability to prevent the death of host photoreceptors, but they can also differentiate into all major retinal cell types to replace lost cells. In vivo experiments, primarily performed in mice, have found that stem cell-derived RPE cells, photoreceptors, and their precursors can survive long-term in animal models without tumorigenicity or immune rejection. Following transplantation, these cells were able to integrate and mature in vivo, forming synapse-like structures with host retinal cells. Furthermore, transplants in mice were able to rescue visual function at a cellular and behavioral level. These promising preclinical results have led to clinical trials testing cell therapy in numerous diseases, including Stargardt macular dystrophy, age-related macular degeneration, retinitis pigmentosa, and central retinal vein occlusion. These trials have demonstrated the safety of cell therapy and have improved visual function in some patients. Scientific advances in the culturing of retinal organoids and the understanding of cell redifferentiation are informing the development of better stem cell therapies, which hold great potential for restoring vision to patients with retinal dystrophies.
2026-05-27 | Subtenon Autologous Platelet-Rich Plasma in Degenerative Retinal Diseases: A Prospective Pilot Study of Safety and Exploratory Functional Signals in Retinitis Pigmentosa and EMAP.
Purpose: To evaluate the safety and feasibility of repeated subtenon administration of autologous platelet-rich plasma (PRP) in patients with degenerative retinal diseases and to explore preliminary, hypothesis-generating functional observations in retinitis pigmentosa (RP) and extensive macular atrophy with pseudodrusen-like appearance (EMAP). Methods: This prospective, open-label, uncontrolled pilot study included 13 patients (6 RP, 7 EMAP) who received three subtenon PRP injections (1.5 mL each) at baseline, Month 2, and Month 4, with follow-up through Month 6. The study was designed primarily to assess safety and feasibility and was not powered or intended to evaluate efficacy. The primary outcome was safety, including adverse events and intraocular pressure changes. Exploratory secondary outcomes included best-corrected visual acuity (BCVA, logMAR), visual field mean deviation (MD), and structural optical coherence tomography (OCT) parameters. Electrophysiological outcomes were analyzed descriptively due to incomplete paired data. Analyses were conducted within diagnostic groups, and no between-group comparisons were performed. Results: All 13 patients completed the study. No serious adverse events or permanent ocular morbidity were observed. Two transient and self-limited adverse events occurred (anterior uveitis and intraocular pressure elevation), both resolving without sequelae. In the overall cohort, BCVA remained stable without statistically significant change. In the RP subgroup, a small exploratory change in BCVA was observed (mean ΔlogMAR -0.09; nominal p = 0.048), corresponding to approximately 4-5 ETDRS letters; however, this finding was associated with wide confidence intervals and limited statistical power and should be interpreted cautiously. In the EMAP subgroup, functional stability was observed without evidence of consistent improvement. Visual field mean deviation and OCT findings were consistent with absence of short-term deterioration across available paired data. Electrophysiological outcomes showed no consistent directional change. Conclusions: Repeated subtenon PRP administration appeared feasible and well tolerated in this small, uncontrolled pilot cohort. Any observed functional changes are preliminary and hypothesis-generating only and do not establish efficacy. Larger, adequately powered controlled studies with standardized endpoints are required to determine the potential role of PRP in degenerative retinal diseases.
2026-05-15 | Inhibitory Circuits Can Restore OFF Pathway Responses in Retinal Prostheses.
One of the first steps in processing visual information is to split the light signal captured by photoreceptors into complementary ON and OFF pathways, which separately encode increases and decreases in luminance. In blind patients with retinal degeneration, optoelectronic prostheses can successfully activate the ON pathway and evoke bright percepts; however, patients do not perceive dark features. This indicates that the OFF pathway is not being activated by existing prosthetics. To quantify OFF pathway deficits, we stimulated retinal ganglion cells (RGCs) in a mouse model of retinitis pigmentosa of either sex with electrical stimulation mimicking retinal prosthetic activation and recorded their voltage responses using whole-cell recording. We found that most OFF RGCs respond with incorrect ON responses, except for one specific subtype of RGC, the OFFα, which retained correct OFF-type responses following the termination of stimulation. We found that these preserved OFF responses were driven by postinhibitory rebound excitation, mediated by hyperpolarization-activated cyclic nucleotide-gated channels. Using a combinatorial genetic approach to achieve chemogenetic control, we identified AII amacrine cells as the presynaptic source driving these electrically evoked OFF responses. These insights into how the OFF pathway responds to artificial stimulation suggest new opportunities to improve prosthetic vision restoration through tuning of stimulation parameters.
other
2026-09-16 | FLVCR1 Variant as a Cause of Retinal and Neurologic Dysfunction in Retinitis Pigmentosa with Coats-Like Vasculopathy: A Case Report.
We report a unique clinical presentation of a patient with undiagnosed neurologic symptoms in the setting of retinitis pigmentosa (RP) with Coats-like reaction and FLVCR1 variant, expanding the presentation of FLVCR1 variants. A 31-year-old Caucasian female with RP with Coats-like reaction initially presented to our clinic in August 2021 with worsening vision. Genetic testing identified the patient as heterozygous for FLVCR1 c.1092 + 5G>A and FLVCR1 c.1058C>T, p.(Thr353Met). The patient notably had a long-standing history of nyctalopia as well as complex neurologic symptoms without diagnosis. Neurologic presentation over 6 years included migraine headaches, decreased extremity strength, seizure-like episodes, and urinary incontinence. Progressive leg weakness and spasms eventually impaired weight bearing and ambulation. On presentation to the clinic again in February 2025, she reported progressive central vision loss, ocular pain OD, and persistent instability in her legs. OCT revealed cystoid macular edema, attenuated retinal vessels, and a large lipid exudation in the fovea OD. The patient was initiated on anti-VEGF therapy in February. Follow-up OCT 1 month later revealed a reduction in lipid exudation. This case underscores the importance of considering an underlying FLVCR1 variant in patients with retinitis pigmentosa and atypical neurologic symptoms. Despite prior genetic testing, this patient's neurologic findings remained undiagnosed, highlighting the need for greater clinical awareness of neuro-ophthalmic manifestations of rare genetic disorders. Anti-VEGF therapy appears effective in reducing lipid exudation in Coats-like retinopathy.
2026-07-24 | DNAJC17 deficiency: A novel inborn error of immunity with TNF-driven autoinflammation.
Inborn Errors of Immunity (IEI) encompass a broad spectrum of monogenic disorders with variable clinical presentations, including recurrent infections, autoimmunity, and systemic inflammation. Loss-of-function mutations in DNAJC17 have been previously linked to retinal dystrophy and hypogammaglobulinemia; however, the complete immunological phenotype and underlying autoinflammatory mechanisms remain poorly characterized. We conducted a comprehensive clinical, molecular, and immunological investigation of three affected individuals from two unrelated consanguineous families. Our evaluation included whole genome sequencing with systematic exclusion of alternative genetic etiologies, quantitative analysis of DNAJC17 mRNA expression, and assessment of intracellular DNAJC17 protein levels. In addition, we performed in-depth immunophenotyping of adaptive and innate immune cell subsets, cytokine profiling, and interferon-stimulated gene expression analysis, alongside longitudinal evaluation of responses to therapeutic interventions. All three patients presented with early-onset retinitis pigmentosa, recurrent fever, lymphadenitis, and hypogammaglobulinemia. Sanger sequencing confirmed a homozygous variant (c.681G>A; p.Ala227=) in DNAJC17 resulting in exon 9 skipping. Comprehensive whole genome analysis excluded pathogenic variants in other immune-related genes. Quantitative RT-PCR demonstrated reduced DNAJC17 mRNA levels and flow cytometry showed decreased intracellular protein levels, consistent with a hypomorphic loss-of-function effect. Immunological evaluation revealed distinct abnormalities in T, B, and NK-cell subsets, with altered monocyte and dendritic cell populations indicating innate and adaptive immune dysregulation. Inflammatory profiling identified increased cytokine activity, including TNF-α and IL-6, alongside mild induction of interferon-stimulated genes. Conventional immunomodulatory therapies failed to achieve sustained remission. In contrast, TNF inhibitor therapy resulted in dramatic clinical improvement with normalization of inflammatory markers, sustained for over three years without significant adverse events. Our findings establish DNAJC17 deficiency as a novel monogenic inborn error of immunity characterized by retinopathy, combined immunodeficiency, and TNF-driven autoinflammation responsive to targeted TNF blockade. The underlying immune abnormalities underscore the essential role of DNAJC17 in maintaining immune homeostasis and mitochondrial function. This work provides mechanistic insights into disease pathogenesis and establishes a rational, precision medicine therapeutic approach for this newly defined syndrome.
2026-06-11 | Multimodal imaging and intravitreal faricimab for polypoidal choroidal vasculopathy associated with a choroidal nevus in genetically confirmed Usher syndrome type 2: a case report.
Usher syndrome is an autosomal recessive disorder characterized by retinitis pigmentosa (RP), sensorineural hearing loss, and vestibular dysfunction. Polypoidal choroidal vasculopathy (PCV) is characterized by branching neovascular networks and polypoidal lesions. While typically classified within the pachychoroid spectrum, PCV can also manifest in eyes without choroidal thickening. Conversely, RP is usually associated with choroidal thinning, which may lead to underdiagnosis of PCV. To the best of our knowledge, PCV has not previously been reported in patients with Usher syndrome. Here, we present the first genetically confirmed case of Usher syndrome type 2 complicated by PCV that was successfully managed with intravitreal faricimab. A 63-year-old man presented with night blindness. The diagnosis of Usher syndrome type 2 was confirmed based on bilateral RP features, moderate sensorineural hearing loss, and two pathogenic USH2A variants. Six years after the initial diagnosis, the patient developed visual disturbance in the left eye, with the best-corrected visual acuity (BCVA) declining to 20/80. Multimodal imaging, including spectral-domain optical coherence tomography, fluorescein angiography, indocyanine green angiography, and swept-source optical coherence tomography angiography, confirmed the diagnosis of PCV. An amelanotic choroidal nevus was also identified on SD-OCT. After five intravitreal faricimab injections, the BCVA improved to 20/30, with a 75% reduction in pigment epithelial detachment height and complete subretinal fluid resolution without adverse effects. To our knowledge, this is the first reported case of PCV associated with a choroidal nevus in a patient with genetically confirmed Usher syndrome type 2. PCV should not be excluded in patients with RP despite characteristic choroidal thinning. Intravitreal faricimab was effective and well-tolerated, suggesting its therapeutic potential in such cases.
2026-06-04 | Targeted antisense oligonucleotide therapy rescues PRPF31 expression in retinitis pigmentosa caused by a splicing mutation.
Pathogenic variants in splicing factors are the second most common cause of autosomal dominant retinitis pigmentosa, with mutations in PRPF31 being the most prevalent. Here, we characterize a novel intronic variant in PRPF31 (c.1074-11C>G) that creates a cryptic 3' splice site, resulting in an aberrantly spliced transcript predicted to encode a protein with an altered C terminus. However, the pathogenic protein is unstable and undetectable in patient-derived induced pluripotent stem cells (iPSCs). In addition, expression of the full-length PRPF31 protein was reduced in patient-derived retinal pigment epithelium (RPE). To correct the splicing defect, we designed a panel of antisense oligonucleotides (ASOs) targeting putative RNA-binding sites in exon 10 and intron 10 and identified a candidate that corrects PRPF31 splicing in a minigene reporter system as well as in patient-derived iPSCs and RPE. We further showed that ASO treatment enhances PRPF31 protein expression in patient-derived iPSC and RPE carrying the intronic mutation, supporting the potential of the ASO-based approach to restore PRPF31 expression in patients with the same or similar splicing defects.
2026-05-27 | TPM1 drives cytoskeleton-immunometabolism coupling and LGALS9/CD45-mediated neuroinflammatory propagation in retinitis pigmentosa.
Retinitis pigmentosa (RP), the most prevalent inherited retinal degeneration, features progressive photoreceptor loss with no approved disease-modifying therapies. While microglia-driven neuroinflammation accelerates RP progression, its sustaining mechanisms remain elusive. Through integrated multiomics profiling of retinal degeneration 10 (rd10) mice, we identify tropomyosin 1 (TPM1) as a previously unrecognized cytoskeletal-immune regulator orchestrating spatial neuroinflammation in RP. Genetic ablation of Tpm1 attenuated microglial reactivity and preserved vision, whereas overexpression triggered self-reinforcing inflammation via four interlocked axes: (i) TPM1-mediated activator protein-1 (AP-1) hyperactivation initiates senescence-associated secretory phenotype (SASP) through mitogen-activated protein kinase (MAPK) kinase/extracellular signal-regulated kinase 3-dependent MAPK signaling; (ii) SASP subsequently mediates reduced phagocytosis; (iii) Tpm1-Apoe/Fabp5 axis disruption precipitates lipid droplet accumulation with cholesterol crystallization; (iv) galectin-9 (LGALS9)/CD45-mediated intermicroglial signaling propagates inflammatory signals across the retina. Our work redefines TPM1 as a linchpin in self-sustaining neurodegeneration cycles, where cytoskeletal dysfunction fuels immunometabolic collapse. These findings unveil precision therapeutic strategies targeting TPM1 hubs-notably the LGALS9/CD45 axis-to disrupt inflammatory cycles while preserving retinal homeostasis.
small molecules
2026-09-26 | Dual Targeting of Galanin Receptor 3 Signaling and Redox Homeostasis Enhances Photoreceptor Survival in Retinas of rd10 Mice.
Retinitis pigmentosa (RP) is a genetically heterogeneous group of inherited retinal degenerative disorders characterized by progressive photoreceptor loss and vision impairment, for which broadly applicable mutation-independent therapies remain limited. To examine the therapeutic potential of combined galanin receptor 3 (GALR3) inhibition and antioxidant therapy in a mutation-independent context, we utilized the rd10 mouse model of RP. We first evaluated the effects of individual treatments with the GALR3 antagonist SNAP-37889 and the antioxidant quercetin, followed by a combined treatment regimen to determine whether simultaneous targeting of neuroinflammatory and oxidative stress pathways provides enhanced retinal protection. Treatment efficacy was assessed using functional and morphological analyses, including electroretinography (ERG) to measure retinal function, optical coherence tomography (OCT) to evaluate retinal structure in vivo, and histological and immunohistochemical analyses to quantify photoreceptor survival and markers of retinal oxidative stress and inflammation. Although the expression levels of individual inflammatory and oxidative stress markers did not consistently exhibit additive responses, the combined treatment produced greater photoreceptor survival and preservation of photopic retinal function than either monotherapy alone. These findings support the hypothesis that simultaneous modulation of oxidative stress and neuroinflammation provides greater neuroprotective benefits, establish a foundation for the development of mutation-independent therapeutic strategies for RP, and identify GALR3 as a promising therapeutic target.
2026-09-16 | Microbiota-mitochondria axis in neurodegenerative disorders and retinal dysfunction: mechanisms and emerging therapeutic opportunities.
The gut microbiota crucial role in maintaining host metabolism, immune homeostasis, intestinal integrity, and mitochondrial function. Emerging evidence suggests that dysregulation of the microbiota-mitochondria axis represents one of the key mechanisms linking gut dysbiosis to the development of neurodegenerative and ocular diseases. The dysbiosis causes disruptions in mitochondrial physiology due to lower levels of short-chain fatty acids, increased intestinal permeability, endotoxemia, oxidative stress, and inflammation. These mechanisms contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, age-related macular degeneration, diabetic retinopathy, retinitis pigmentosa, and central serous chorioretinopathy. Environmental factors such as unhealthy dietary patterns, excessive antibiotic use, and prolonged exposure to artificial blue light may exacerbate dysbiosis and further disrupt mitochondrial homeostasis, thereby contributing to disease progression. We also elaborated the emerging therapeutic strategies targeting both the gut microbiota and mitochondrial function, including next-generation probiotics, postbiotics, dietary interventions, mitochondria-targeted antioxidants, NAD+ precursors, and precision medicine approaches. Collectively, current evidence represents the microbiota-mitochondria axis as a one of the promising mechanistic and therapeutic targets for neurodegenerative and ocular diseases. However, most therapeutic evidence discussed in this review is derived from preclinical studies, with relatively limited clinical validation. Future well-designed longitudinal studies and randomized clinical trials are essential to establish efficacy, safety, and translational applicability in humans.
2026-09-15 | PGC-1α and PPARs cooperatively mediate photoreceptor neuroprotection in rd1 mouse inherited retinal degeneration.
Retinitis pigmentosa (RP) is a group of inherited diseases characterized by primary rod photoreceptor dysfunction and progressive cone cell death. Due to their very high energy demand, the degeneration of photoreceptors may be linked to insufficient energy supply or metabolic imbalance. Critical transcription factors that regulate metabolism, such as peroxisome proliferator-activated receptors (PPARs) and PPAR gamma coactivator 1α (PGC-1α), have been found to play important roles in neurodegenerative diseases, but their potential roles in RP have yet not been elucidated. Here, organotypic retinal explant cultures derived from retinal degeneration 1 (rd1) mice were used to investigate the effects of PPARα, PPARγ, PPARβ/δ agonists, as well as PGC-1α activation and inhibition. Photoreceptor death was quantified using the TUNEL assay, while in situ activity assays were used to monitor effects of PPARs and PGC-1α on poly (ADP-ribose) polymerase (PARP) and calpain activity. Generation of poly (ADP-ribose) (PAR) and activation of calpain-1 and calpain-2 were evaluated by immunostaining. PGC-1α/PPAR-associated transcriptional changes were assessed by RT-qPCR. We found that PPARβ/δ agonists had limited effects, while treatment targeting PPARα, PPARγ, and PGC-1α significantly reduced photoreceptor death and PARP activity in rd1 retina. RT-qPCR analysis in treated rd1 retina confirmed upregulation of genes downstream of PGC-1α/PPAR signaling. Stimulation of the histone deacetylase sirtuin-1, an upstream regulator of PGC-1α, had no beneficial effect on photoreceptor viability unless combined with PARP inhibition. Furthermore, PPARγ and PGC-1α effectively suppressed overall calpain activity and overactivation of calpain-2, alleviating photoreceptor degeneration caused by Ca2+ imbalance. In summary, our data support the concept of a PARP-sirtuin-1-PGC-1α-PPAR-PARP feedback control that connects defective energy metabolism to photoreceptor degeneration. Specifically, our findings suggest that PPARα, PPARγ, and PGC-1α cooperate to preserve photoreceptor viability, highlighting PPAR-signaling as a promising target for future therapeutic interventions.
2026-09-11 | herapeutic Possibilities of N-acetylcysteine in Retinitis Pigmentosa: A Scoping Review
This scoping review aims to analyze the extent of evidence regarding ophthalmological manifestations associated with cluster headache, including clinical findings, potential pathophysiological mechanisms, and their relevance to clinical recognition and the differential diagnosis of the disease. The guiding question was structured using the PCC mnemonic: "What is the evidence regarding the therapeutic use of N-acetylcysteine in retinitis pigmentosa?". Additionally, four specific questions were defined as key elements. The literature search will be conducted using the PubMed, BVS, and SciELO databases. Studies resulting from the searches will be exported to Rayyan.ai software and selected in two phases based on pre-established criteria. Stage I will consist of screening articles by title and abstract, while Stage II will involve a full-text review of the selected articles. A qualitative synthesis will be prepared based on data extracted from the selected studies. The extracted data will also be summarized in a descriptive table containing concise answers to all specific questions.
2026-08-28 | Novel insights of minocycline as a neurovascular protective agent in retinitis pigmentosa.
Retinitis pigmentosa (RP) is characterised by progressive photoreceptor degeneration accompanied by vascular abnormalities. We have previously demonstrated that minocycline exhibits therapeutic potential in RP. This trial aimed to evaluate its neurovascular protective effects. Patients with RP were enrolled and administered 100 mg of minocycline once daily for 12 months. A total of 32 eyes from 16 participants were included. The primary outcomes were changes in retinal and choroidal vasculature, including vessel density, lacunarity, foveal avascular zone (FAZ) area, fluorescein angiography (FA) score and subfoveal choroidal thickness (SFCT). The secondary outcomes included changes in photoreceptor structure and function, including ellipsoid zone width, best-corrected visual acuity (BCVA), mean macular sensitivity, mean deviation (MD) and error score. Adverse events were recorded. Additionally, Rd1 mice were used to further investigate the vascular effects of minocycline. After 12-month minocycline treatment, RP patients exhibited increased vessel density in both the retinal superficial capillary plexus (SCP) and retinal deep capillary plexus (DCP), accompanied by reduced FAZ area and decreased lacunarity in the SCP and DCP. FA score and SFCT remained stable, as did all secondary outcomes. A total of 24 adverse events were reported in 8 patients, and all resolved spontaneously without additional intervention. Additional experiments in Rd1 mice demonstrated improved retinal vascular abnormalities and preserved blood-retinal barrier integrity, accompanied by upregulated expression of tight junction proteins. Oral 100 mg minocycline once daily for 12 months was beneficial to protect vascular integrity and stabilise photoreceptor structure and function with good tolerability.
proteins
2026-09-23 | Photobiology in ophthalmology: from evolutionary adaptation to translational therapeutics.
Life has evolved under continuous exposure to solar light, and the emergence of the eye during the Cambrian period is thought to have accelerated biological diversification. Beyond vision, light acts as a biological regulator of metabolism and tissue organization. To elucidate ocular disease mechanisms and develop new therapies, we have investigated how light is sensed by the eye and coupled to physiological and pathological responses. This review reexamines the eye as a photoreceptive organ and summarizes recent advances showing how light input governs retinal metabolism, refractive development, and visual restoration. First, we describe how retinal light reception is linked to oxygen-dependent metabolic control. As one of the most oxygen-demanding tissues, the retina relies on hypoxia-inducible factor (HIF) signaling to coordinate angiogenesis, mitochondrial metabolism, fibrosis, and neuronal survival. Beyond pathological neovascularization, disrupted light-metabolic coupling contributes to neurodegeneration and subretinal scarring. Screening of natural compounds identified HIF regulators with therapeutic efficacy, and optical approaches were developed to detect hypoxia-induced intraocular cytokines noninvasively. Second, we show that environmental light regulates ocular growth in ways beyond image formation. Violet light activates nonvisual photoreception via OPN5-expressing retinal ganglion cells, engaging an OPN5-EGR1 pathway that preserves choroidal thickness and suppresses axial elongation through coordinated retina-brain-choroid-sclera interactions. Third, we demonstrate that light itself becomes therapeutic through optogenetic visual restoration. Chimeric rhodopsins confer high-sensitivity light responsiveness to surviving inner retinal neurons and have recently entered first-in-human clinical evaluation for advanced retinitis pigmentosa. These findings establish photobiology as a unifying framework for translational ophthalmology.
2026-08-15 | Phase I/IIa Study of an Intravitreal Optogenetic Therapy (AGN-151597) in Patients with Advanced Retinitis Pigmentosa.
Retinitis pigmentosa is an incurable, inherited retinal disease that causes vision loss and blindness. We evaluated the safety and preliminary efficacy of AGN-151597, a mutation-independent optogenetic therapy encoding channelrhodopsin-2, in patients with advanced retinitis pigmentosa. First-in-human, phase I/IIa, open-label, dose-escalation study (1 study eye/participant). Participants had advanced retinitis pigmentosa with severely impaired visual function. Participants received an intravitreal injection of low-dose (4.3 × 1010 vg/eye; n = 3), mid-dose (1.4 × 1011 vg/eye; n = 4), or high-dose (4.3 × 1011vg/eye; n = 7) AGN-151597 in the study eye. The study duration was 24 months followed by a 3-year safety extension. The primary safety endpoint was safety at 6 months as assessed by intraocular pressure and changes in visual acuity, full-field sensitivity, ambulation, and visual anatomical parameters. Efficacy measures included changes in visual acuity, full-field stimulus threshold (FST), ambulation, object detection/discrimination, visual evoked potentials, electroretinography, and visual function-related quality of life (questionnaire). Fourteen patients (median age 62 years) were enrolled. AGN-151597 treatment resulted in no clinically significant changes in ocular safety assessments. Most treatment-emergent adverse events (TEAEs) were ocular; none were severe. The most common treatment-related TEAE was transient increased intraocular pressure (n = 3). No clinically significant efficacy was observed. Full-field stimulus threshold measurements in both eyes showed good agreement between the screening and baseline visits, with coefficients of repeatability of 6.2 for blue light, 2.7 for red light, and 5.3 for white light. Overall mean FST in study eyes at baseline was -13.5 dB for blue light, -1.0 dB for red light, and -5.2 dB for white light. Participants' mean FST changed similarly in both eyes over 24 months for each light stimulus. There was no evidence of AGN-151597 efficacy in slowing vision decline in patients with advanced retinitis pigmentosa. However, the absence of safety concerns over 5 years after intravitreal administration of an adeno-associated virus type 2 vector-delivered genetic medicine is encouraging and supports further gene therapy endeavors to enhance visual function in this devastating retinal disease. Full-field stimulus threshold is a reliable test in patients with poor vision. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
2026-08-04 | WDR34 Deficiency Disrupts Retrograde Intraflagellar Transport and Induces Unfolded Protein Response-Driven Inflammation and Retinal Degeneration.
Retinitis pigmentosa (RP) is a hereditary retinal disease characterized by progressive photoreceptor cell (PRC) degeneration. WD repeat domain 34 (WDR34), an intermediate chain of dynein-2, is essential for retrograde intraflagellar transport (IFT). However, the mechanisms by which WDR34 deficiency causes retinal degeneration remain unclear. This study aims to investigate the impact of WDR34 deficiency on retrograde IFT and its contribution to retinal degeneration. WDR34 deficiency was modeled in vivo via subretinal injection of adeno-associated virus-shRNA-WDR34 and in vitro by CRISPR/Cas9-mediated knockout in 661W cells. Retinal degeneration and IFT defects were assessed by histologic, functional, and ultrastructural analyses. Proteomic analysis followed by in vivo validation was used to investigate the molecular mechanism underlying WDR34-deficient retinal degeneration. WDR34 knockdown induced progressive retinal degeneration characterized by PRC apoptosis, gradual outer nuclear layer thinning, reduced electroretinography responses, and outer segment shortening. WDR34 deficiency impaired retrograde IFT and caused rhodopsin and opsin mislocalization. These alterations induced endoplasmic reticulum stress and unfolded protein response (UPR) activation, activating the IRE1α/TRAF2/NF-κB signaling pathway, ultimately contributing to retinal inflammation and degeneration. WDR34 is crucial for maintaining retrograde IFT in PRCs. WDR34 deficiency disrupts outer segment maintenance and triggers UPR-mediated inflammatory responses and apoptosis, ultimately leading to retinal degeneration. This study reveals a novel mechanistic link among WDR34, retrograde IFT, ciliopathies, and retinal degeneration, providing potential therapeutic insights for ciliopathy-associated RP.
2026-07-27 | The Drosophila CEBPG homolog Irbp18 partners with crc (ATF4) to mediate the integrated stress response in degenerative disease models.
The integrated stress response (ISR) coordinates cellular adaptation to diverse stress conditions. In Drosophila, two bZIP transcription factors, Xrp1 and crc (ATF4 homolog), are induced during ISR. Crc protein can dimerize with two CEBP factors in vitro, but the in vivo relevance of those interactions remained unknown. Here, we report that the CEBPG homolog, Irbp18, is an essential partner of crc during ISR. Specifically, Irbp18 is broadly required for the transcriptional induction of ISR target genes in the photoreceptors of ninaEG69D, a Drosophila model of retinitis pigmentosa. Moreover, CUT&RUN analysis indicates that Irbp18 loss reduces or abolishes crc binding to target DNAs in photoreceptors and impairs crc's ability to induce target transcripts upon overexpression. Functionally, Irbp18 loss causes retinal degeneration and suppresses ISR signaling in parkin mutants, a model of Parkinson's disease. Together, these findings identify Irbp18 as a cofactor for crc, impacting pathological outcomes in Drosophila models of degeneration.
2026-05-15 | Chromophore-loaded CRALBP mutant proteins restore rod function in chromophore-deficient mice.
Visual function depends critically on the supply of visual chromophore, 11-cis-retinal, to the photoreceptor cells in the retina. Chromophore deficiency due to aging or mutations affecting its delivery and recycling in the eye by the retinal pigment epithelium (RPE) and the Müller cells cause a wide range of visual disorders. The cellular retinaldehyde-binding protein (CRALBP), expressed in both compartments, crucially aids in accelerating the recycling of visual chromophore. Here, we explored the potential of chromophore-loaded CRALBP in restoring vision in chromophore-deficient mice. We tested wild-type human CRALBP and its redox-sensitive A212C:T250C mutant, both pre-loaded with 9-cis-retinal, for their efficacy in delivering chromophore to the retina and restoring rod photoreceptor function in RPE65-deficient mice that cannot produce visual chromophore. We observed robust restoration of rod function both in the isolated retina treated with chromophore-loaded CRALBP and in vivo after a single intravitreal injection of wild-type or mutant CRALBP proteins. Notably, the recovery of rod visual function after exposure to bright light that photoactivated most of the visual pigment was greatly accelerated in CRALBP-treated RPE65-knockout mice compared to wild-type control mice. Together, our results highlight the therapeutic potential of CRALBP complexes in efficiently delivering visual chromophore to retinal rod photoreceptors.
gene therapies
2026-09-22 | A novel PRPF31 variant associated with autosomal dominant retinitis pigmentosa in Japanese families.
PRPF31-associated inherited retinal dystrophy is an autosomal dominant form of retinitis pigmentosa (RP), typically caused by haploinsufficiency. Although affected individuals generally exhibit early-onset nyctalopia and progressive visual field loss, the clinical and genetic characteristics associated with individual PRPF31 variants remain incompletely defined, particularly for variants initially classified as variants of uncertain significance (VUS). We investigated five unrelated families carrying the same heterozygous PRPF31 variant, c.613_615del (p.Tyr205del), which was previously classified as a VUS. Clinical and genetic data were systematically collected from 15 individuals carrying the variant. Segregation patterns and clinical findings were assessed in relation to the established disease mechanism. In addition, cross-sectional clinical characteristics were analyzed in 35 individuals with PRPF31-associated RP to characterize the disease phenotype and progression. The accumulated familial and phenotypic evidence provided additional support for the pathogenicity of p. Tyr205del, enabling its reclassification as a likely pathogenic variant. Analysis of 35 affected individuals showed that PRPF31-associated RP follows the typical progression pattern of classical RP, with rod-predominant degeneration followed by progressive deterioration of central visual function. Systematic accumulation of clinical and familial data across multiple cases can provide important evidence for variant interpretation, particularly for rare PRPF31 variants initially classified as VUS. Integrating genetic, segregation, and phenotypic information may improve diagnostic accuracy and facilitate the identification of patients who may benefit from future PRPF31-targeted therapies.
2026-09-15 | InsightRP2-An Interdisciplinary Approach Toward Therapy Development in RP2-Associated Retinopathy.
Advancing the development of specific gene therapies for rare genetic eye disorders is a major challenge in modern translational vision research. It requires integrated clinical, molecular, mechanistic, and regulatory expertise, yet these aspects are often addressed in isolation. Combining complementary skills, knowledge, and expertise within an integrated, highly interactive research framework has the capacity to drive and advance therapeutic development. Moreover, early-stage involvement of patients and targeted clinical observation, alongside molecular and therapeutic research, potentially enable clinical trial readiness and support the translation of preclinical therapeutic innovations into clinical care. In this Perspective article, we present the InsightRP2 framework, an integrated translational strategy that incorporates clinical data, artificial intelligence-supported imaging analysis, experimental disease modeling, and adeno-associated virus design with the aim to facilitate the development of a targeted gene therapy for RP2-associated retinitis pigmentosa.
2026-09-14 | Progress in gene therapy for RPGR-associated X-linked retinitis pigmentosa.
X-linked retinitis pigmentosa (XLRP) caused by pathogenic variants in RPGR is among the most severe inherited retinal dystrophies, with childhood-onset nyctalopia followed by progressive visual-field constriction and central visual loss. The purine-rich ORF15 terminal exon has driven sustained development of adeno-associated virus-mediated gene supplementation. This review summarizes the molecular biology of RPGR, the challenge of stabilizing the ORF15 transgene, the principal clinical programs, and endpoint selection in pivotal trials. Clinical development has followed two transgene strategies: codon optimization preserving full-length RPGRORF15, or a construct containing a 126-amino-acid deletion removing approximately 36% of the Glu-Gly-rich region and 6 of 11 identified glutamylation consensus motifs. Beyond transgene design, appropriate endpoint selection is critical to demonstrating therapeutic efficacy in RPGR-XLRP. The multi-luminance mobility test was developed for RPE65-associated retinal dystrophy, where visual-cycle restoration can rapidly improve night vision, and may be less suited to slowly progressive RPGR-XLRP. Microperimetry can detect localized changes in retinal sensitivity but requires careful standardization and repeated baseline testing to minimize learning effects. Low-luminance visual acuity (LLVA) represents an attractive primary functional endpoint for: it is simple, standardized and clinically meaningful, while challenging central visual function under conditions in which RPGR-XLRP patients may be impaired despite preserved conventional acuity. Importantly, XIRIUS demonstrated treatment-related improvements in LLVA and mean microperimetry sensitivity, supporting the responsiveness of both measures to therapeutic intervention in RPGR-XLRP. LLVA and microperimetry are well suited to primary efficacy assessment in RPGR-XLRP, with endpoint selection guided by disease stage and the anticipated treatment effect and supported by complementary structural biomarkers.
2026-09-09 | Bionic vision technologies: progress and perspectives on retinal prostheses and optogenetics for the treatment of advanced retinal degeneration.
Advanced degenerative retinal diseases [e.g., retinitis pigmentosa (RP) and age-related macular degeneration (AMD)] are characterized by irreversible photoreceptor loss, and conventional interventions rarely prevent progression to profound vision loss at advanced stages. Retinal prostheses and optogenetic therapies are two leading bionic strategies to bypass absent photoreceptors, yet both are limited by a shared "encoding-biointerface" bottleneck: converting external scenes into interpretable neural activity in surviving retinal circuits with adequate selectivity, safety margins, and long-term stability. This review critically compares the two approaches in spatial resolution, neural adaptation, and biosafety, while explicitly distinguishing clinical evidence from preclinical and proof-of-concept studies. Retinal prostheses provide near-term light perception and limited form vision but are constrained by current spread, non-selective pathway/axon recruitment, interface reactions, and cortical decoding burden. Optogenetic restoration offers cell-type-biased reactivation and potentially more physiological processing, but currently remains coupled to external light-delivery hardware and is limited by scattering, heterogeneous transduction, safety-limited irradiance, restricted dynamic range, and adeno-associated virus (AAV)-related inflammatory risk. We highlight emerging integrative directions, including opto-electronic hybrid interfaces, adaptive encoding, broadband subretinal nanomaterial-based photovoltaic nanoprostheses, and experimental acoustic modalities (e.g., focused ultrasound and sonogenetics), alongside ethical and accessibility considerations for translation.
2026-09-08 | Generation of isogenic gene-corrected cell lines from a USH2A-RP patient-derived iPS cell line.
Comparative studies using induced pluripotent stem cells (iPSCs) from patients with those from healthy individuals as controls are flawed by genetic background contribution to disease phenotype. Here, we used precise gene editing to generate gene-corrected isogenic control lines for a single pathogenic variant in the USH2A gene (c.2276G > T) associated with retinitis pigmentosa (RP). Both homozygously and heterozygously corrected cell lines were successfully generated. These cell lines will serve to unravel RP phenotype differences specific to the USH2A mutation upon their conversion into disease relevant cell types.
cell therapies
2026-09-25 | Stem Cell-Based Strategies for Retinal Cell Restoration.
Retinal degenerative diseases, including age-related macular degeneration, retinitis pigmentosa, diabetic retinopathy, and inherited retinal dystrophies, are among the leading causes of irreversible vision loss and blindness worldwide. Current treatments primarily slow disease progression and are unable to restore lost retinal cells or visual function, highlighting the need for regenerative therapeutic strategies. Stem cell-based therapies have emerged as a promising approach for retinal repair through multiple mechanisms, including retinal cell replacement, stimulation of endogenous regeneration, cellular reprogramming, immunomodulation, and paracrine signaling. This narrative review provides a comprehensive overview of the major stem cell sources investigated for retinal regeneration. In addition, the roles of extracellular vesicles and retinal organoids as emerging therapeutic platforms are discussed. Particular emphasis is placed on comparing the biological rationale, therapeutic potential, current preclinical and clinical evidence, and translational readiness of each approach. Despite encouraging progress, several challenges continue to limit routine clinical application, including poor survival and integration of transplanted cells, immune rejection, tumorigenicity, genomic instability, variability in differentiation efficiency, manufacturing standardization, and long-term safety. Continued advances in stem cell biology, tissue engineering, gene editing, and clinical trial design are expected to accelerate the development of safe and effective regenerative therapies for retinal diseases.
2026-07-09 | Photoreceptor-targeted engineered exosomes encapsulating black phosphorus quantum dots for alleviating photoreceptor degeneration.
Photoreceptor degeneration is a major cause of irreversible visual impairment worldwide, most notably in retinitis pigmentosa (RP). Here, we developed a dual-targeted therapeutic nanoplatform by loading black phosphorus quantum dots (BPQDs) into human dental pulp mesenchymal stem cell-derived exosomes (hDPSC-Exos) and surface-modifying with cell-penetrating peptide transactivated transcription (TAT) and photoreceptor-specific peptide MH42, namely TAT/MH42-engineered black phosphorus quantum dot-loaded exosomes (M/T-BPQD@Exos). M/T-BPQD@Exos showed typical exosomal morphology and good uniformity. In vitro, M/T-BPQD@Exos effectively protected 661 W photoreceptor cells against N-methyl-N-nitrosourea (MNU) injury. In vivo, M/T-BPQD@Exos specifically accumulated in the outer nuclear layer (ONL) and significantly preserved retinal structure and visual function in MNU-induced photoreceptor degeneration rats. Biosafety assessment confirmed no obvious systemic toxicity and inflammation. Mechanistically, M/T-BPQD@Exos alleviated calcium overload, maintained mitochondrial integrity, and suppressed mitochondrial apoptosis by regulating Bcl-2, Bax, and cleaved caspase-3. This study provides a safe and precise strategy for photoreceptor protection in retinal degenerative diseases.
2026-05-31 | Stem cell therapy in retinal disease.
Stem cell therapy presents a new solution to cure degenerative diseases of the retina, which normally have limited ability to regenerate after injury. Stem cells are cells capable of self-renewal and differentiation into more specialized cells, and can be derived from both embryonic and adult sources. This definition encompasses a heterogeneous group of cells possessing varied potency and characteristics. Current attempts in applying stem cell technology to the retina have primarily focused on regenerating the retinal pigment epithelium (RPE) and light-sensing photoreceptor cells. They have not only shown the ability to prevent the death of host photoreceptors, but they can also differentiate into all major retinal cell types to replace lost cells. In vivo experiments, primarily performed in mice, have found that stem cell-derived RPE cells, photoreceptors, and their precursors can survive long-term in animal models without tumorigenicity or immune rejection. Following transplantation, these cells were able to integrate and mature in vivo, forming synapse-like structures with host retinal cells. Furthermore, transplants in mice were able to rescue visual function at a cellular and behavioral level. These promising preclinical results have led to clinical trials testing cell therapy in numerous diseases, including Stargardt macular dystrophy, age-related macular degeneration, retinitis pigmentosa, and central retinal vein occlusion. These trials have demonstrated the safety of cell therapy and have improved visual function in some patients. Scientific advances in the culturing of retinal organoids and the understanding of cell redifferentiation are informing the development of better stem cell therapies, which hold great potential for restoring vision to patients with retinal dystrophies.
2026-05-27 | Subtenon Autologous Platelet-Rich Plasma in Degenerative Retinal Diseases: A Prospective Pilot Study of Safety and Exploratory Functional Signals in Retinitis Pigmentosa and EMAP.
Purpose: To evaluate the safety and feasibility of repeated subtenon administration of autologous platelet-rich plasma (PRP) in patients with degenerative retinal diseases and to explore preliminary, hypothesis-generating functional observations in retinitis pigmentosa (RP) and extensive macular atrophy with pseudodrusen-like appearance (EMAP). Methods: This prospective, open-label, uncontrolled pilot study included 13 patients (6 RP, 7 EMAP) who received three subtenon PRP injections (1.5 mL each) at baseline, Month 2, and Month 4, with follow-up through Month 6. The study was designed primarily to assess safety and feasibility and was not powered or intended to evaluate efficacy. The primary outcome was safety, including adverse events and intraocular pressure changes. Exploratory secondary outcomes included best-corrected visual acuity (BCVA, logMAR), visual field mean deviation (MD), and structural optical coherence tomography (OCT) parameters. Electrophysiological outcomes were analyzed descriptively due to incomplete paired data. Analyses were conducted within diagnostic groups, and no between-group comparisons were performed. Results: All 13 patients completed the study. No serious adverse events or permanent ocular morbidity were observed. Two transient and self-limited adverse events occurred (anterior uveitis and intraocular pressure elevation), both resolving without sequelae. In the overall cohort, BCVA remained stable without statistically significant change. In the RP subgroup, a small exploratory change in BCVA was observed (mean ΔlogMAR -0.09; nominal p = 0.048), corresponding to approximately 4-5 ETDRS letters; however, this finding was associated with wide confidence intervals and limited statistical power and should be interpreted cautiously. In the EMAP subgroup, functional stability was observed without evidence of consistent improvement. Visual field mean deviation and OCT findings were consistent with absence of short-term deterioration across available paired data. Electrophysiological outcomes showed no consistent directional change. Conclusions: Repeated subtenon PRP administration appeared feasible and well tolerated in this small, uncontrolled pilot cohort. Any observed functional changes are preliminary and hypothesis-generating only and do not establish efficacy. Larger, adequately powered controlled studies with standardized endpoints are required to determine the potential role of PRP in degenerative retinal diseases.
2026-05-15 | Inhibitory Circuits Can Restore OFF Pathway Responses in Retinal Prostheses.
One of the first steps in processing visual information is to split the light signal captured by photoreceptors into complementary ON and OFF pathways, which separately encode increases and decreases in luminance. In blind patients with retinal degeneration, optoelectronic prostheses can successfully activate the ON pathway and evoke bright percepts; however, patients do not perceive dark features. This indicates that the OFF pathway is not being activated by existing prosthetics. To quantify OFF pathway deficits, we stimulated retinal ganglion cells (RGCs) in a mouse model of retinitis pigmentosa of either sex with electrical stimulation mimicking retinal prosthetic activation and recorded their voltage responses using whole-cell recording. We found that most OFF RGCs respond with incorrect ON responses, except for one specific subtype of RGC, the OFFα, which retained correct OFF-type responses following the termination of stimulation. We found that these preserved OFF responses were driven by postinhibitory rebound excitation, mediated by hyperpolarization-activated cyclic nucleotide-gated channels. Using a combinatorial genetic approach to achieve chemogenetic control, we identified AII amacrine cells as the presynaptic source driving these electrically evoked OFF responses. These insights into how the OFF pathway responds to artificial stimulation suggest new opportunities to improve prosthetic vision restoration through tuning of stimulation parameters.
other
2026-09-16 | FLVCR1 Variant as a Cause of Retinal and Neurologic Dysfunction in Retinitis Pigmentosa with Coats-Like Vasculopathy: A Case Report.
We report a unique clinical presentation of a patient with undiagnosed neurologic symptoms in the setting of retinitis pigmentosa (RP) with Coats-like reaction and FLVCR1 variant, expanding the presentation of FLVCR1 variants. A 31-year-old Caucasian female with RP with Coats-like reaction initially presented to our clinic in August 2021 with worsening vision. Genetic testing identified the patient as heterozygous for FLVCR1 c.1092 + 5G>A and FLVCR1 c.1058C>T, p.(Thr353Met). The patient notably had a long-standing history of nyctalopia as well as complex neurologic symptoms without diagnosis. Neurologic presentation over 6 years included migraine headaches, decreased extremity strength, seizure-like episodes, and urinary incontinence. Progressive leg weakness and spasms eventually impaired weight bearing and ambulation. On presentation to the clinic again in February 2025, she reported progressive central vision loss, ocular pain OD, and persistent instability in her legs. OCT revealed cystoid macular edema, attenuated retinal vessels, and a large lipid exudation in the fovea OD. The patient was initiated on anti-VEGF therapy in February. Follow-up OCT 1 month later revealed a reduction in lipid exudation. This case underscores the importance of considering an underlying FLVCR1 variant in patients with retinitis pigmentosa and atypical neurologic symptoms. Despite prior genetic testing, this patient's neurologic findings remained undiagnosed, highlighting the need for greater clinical awareness of neuro-ophthalmic manifestations of rare genetic disorders. Anti-VEGF therapy appears effective in reducing lipid exudation in Coats-like retinopathy.
2026-07-24 | DNAJC17 deficiency: A novel inborn error of immunity with TNF-driven autoinflammation.
Inborn Errors of Immunity (IEI) encompass a broad spectrum of monogenic disorders with variable clinical presentations, including recurrent infections, autoimmunity, and systemic inflammation. Loss-of-function mutations in DNAJC17 have been previously linked to retinal dystrophy and hypogammaglobulinemia; however, the complete immunological phenotype and underlying autoinflammatory mechanisms remain poorly characterized. We conducted a comprehensive clinical, molecular, and immunological investigation of three affected individuals from two unrelated consanguineous families. Our evaluation included whole genome sequencing with systematic exclusion of alternative genetic etiologies, quantitative analysis of DNAJC17 mRNA expression, and assessment of intracellular DNAJC17 protein levels. In addition, we performed in-depth immunophenotyping of adaptive and innate immune cell subsets, cytokine profiling, and interferon-stimulated gene expression analysis, alongside longitudinal evaluation of responses to therapeutic interventions. All three patients presented with early-onset retinitis pigmentosa, recurrent fever, lymphadenitis, and hypogammaglobulinemia. Sanger sequencing confirmed a homozygous variant (c.681G>A; p.Ala227=) in DNAJC17 resulting in exon 9 skipping. Comprehensive whole genome analysis excluded pathogenic variants in other immune-related genes. Quantitative RT-PCR demonstrated reduced DNAJC17 mRNA levels and flow cytometry showed decreased intracellular protein levels, consistent with a hypomorphic loss-of-function effect. Immunological evaluation revealed distinct abnormalities in T, B, and NK-cell subsets, with altered monocyte and dendritic cell populations indicating innate and adaptive immune dysregulation. Inflammatory profiling identified increased cytokine activity, including TNF-α and IL-6, alongside mild induction of interferon-stimulated genes. Conventional immunomodulatory therapies failed to achieve sustained remission. In contrast, TNF inhibitor therapy resulted in dramatic clinical improvement with normalization of inflammatory markers, sustained for over three years without significant adverse events. Our findings establish DNAJC17 deficiency as a novel monogenic inborn error of immunity characterized by retinopathy, combined immunodeficiency, and TNF-driven autoinflammation responsive to targeted TNF blockade. The underlying immune abnormalities underscore the essential role of DNAJC17 in maintaining immune homeostasis and mitochondrial function. This work provides mechanistic insights into disease pathogenesis and establishes a rational, precision medicine therapeutic approach for this newly defined syndrome.
2026-06-11 | Multimodal imaging and intravitreal faricimab for polypoidal choroidal vasculopathy associated with a choroidal nevus in genetically confirmed Usher syndrome type 2: a case report.
Usher syndrome is an autosomal recessive disorder characterized by retinitis pigmentosa (RP), sensorineural hearing loss, and vestibular dysfunction. Polypoidal choroidal vasculopathy (PCV) is characterized by branching neovascular networks and polypoidal lesions. While typically classified within the pachychoroid spectrum, PCV can also manifest in eyes without choroidal thickening. Conversely, RP is usually associated with choroidal thinning, which may lead to underdiagnosis of PCV. To the best of our knowledge, PCV has not previously been reported in patients with Usher syndrome. Here, we present the first genetically confirmed case of Usher syndrome type 2 complicated by PCV that was successfully managed with intravitreal faricimab. A 63-year-old man presented with night blindness. The diagnosis of Usher syndrome type 2 was confirmed based on bilateral RP features, moderate sensorineural hearing loss, and two pathogenic USH2A variants. Six years after the initial diagnosis, the patient developed visual disturbance in the left eye, with the best-corrected visual acuity (BCVA) declining to 20/80. Multimodal imaging, including spectral-domain optical coherence tomography, fluorescein angiography, indocyanine green angiography, and swept-source optical coherence tomography angiography, confirmed the diagnosis of PCV. An amelanotic choroidal nevus was also identified on SD-OCT. After five intravitreal faricimab injections, the BCVA improved to 20/30, with a 75% reduction in pigment epithelial detachment height and complete subretinal fluid resolution without adverse effects. To our knowledge, this is the first reported case of PCV associated with a choroidal nevus in a patient with genetically confirmed Usher syndrome type 2. PCV should not be excluded in patients with RP despite characteristic choroidal thinning. Intravitreal faricimab was effective and well-tolerated, suggesting its therapeutic potential in such cases.
2026-06-04 | Targeted antisense oligonucleotide therapy rescues PRPF31 expression in retinitis pigmentosa caused by a splicing mutation.
Pathogenic variants in splicing factors are the second most common cause of autosomal dominant retinitis pigmentosa, with mutations in PRPF31 being the most prevalent. Here, we characterize a novel intronic variant in PRPF31 (c.1074-11C>G) that creates a cryptic 3' splice site, resulting in an aberrantly spliced transcript predicted to encode a protein with an altered C terminus. However, the pathogenic protein is unstable and undetectable in patient-derived induced pluripotent stem cells (iPSCs). In addition, expression of the full-length PRPF31 protein was reduced in patient-derived retinal pigment epithelium (RPE). To correct the splicing defect, we designed a panel of antisense oligonucleotides (ASOs) targeting putative RNA-binding sites in exon 10 and intron 10 and identified a candidate that corrects PRPF31 splicing in a minigene reporter system as well as in patient-derived iPSCs and RPE. We further showed that ASO treatment enhances PRPF31 protein expression in patient-derived iPSC and RPE carrying the intronic mutation, supporting the potential of the ASO-based approach to restore PRPF31 expression in patients with the same or similar splicing defects.
2026-05-27 | TPM1 drives cytoskeleton-immunometabolism coupling and LGALS9/CD45-mediated neuroinflammatory propagation in retinitis pigmentosa.
Retinitis pigmentosa (RP), the most prevalent inherited retinal degeneration, features progressive photoreceptor loss with no approved disease-modifying therapies. While microglia-driven neuroinflammation accelerates RP progression, its sustaining mechanisms remain elusive. Through integrated multiomics profiling of retinal degeneration 10 (rd10) mice, we identify tropomyosin 1 (TPM1) as a previously unrecognized cytoskeletal-immune regulator orchestrating spatial neuroinflammation in RP. Genetic ablation of Tpm1 attenuated microglial reactivity and preserved vision, whereas overexpression triggered self-reinforcing inflammation via four interlocked axes: (i) TPM1-mediated activator protein-1 (AP-1) hyperactivation initiates senescence-associated secretory phenotype (SASP) through mitogen-activated protein kinase (MAPK) kinase/extracellular signal-regulated kinase 3-dependent MAPK signaling; (ii) SASP subsequently mediates reduced phagocytosis; (iii) Tpm1-Apoe/Fabp5 axis disruption precipitates lipid droplet accumulation with cholesterol crystallization; (iv) galectin-9 (LGALS9)/CD45-mediated intermicroglial signaling propagates inflammatory signals across the retina. Our work redefines TPM1 as a linchpin in self-sustaining neurodegeneration cycles, where cytoskeletal dysfunction fuels immunometabolic collapse. These findings unveil precision therapeutic strategies targeting TPM1 hubs-notably the LGALS9/CD45 axis-to disrupt inflammatory cycles while preserving retinal homeostasis.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
98 orphan drug designations for Retinitis pigmentosa, including 1 approved therapy.
98 orphan drug designations for Retinitis pigmentosa, including 1 approved therapy.
Drug | Therapy type | Orphan designation | Clinical trial status | Sponsor |
|---|---|---|---|---|
AAV-mediated anti-PROX1 gene therapy (AAV2-anti-PROX1-scFvFc) | gene therapies | FDA | — | Celliaz Ltd. |
retinal cells derived from allogeneic human induced pluripotent stem cell line | cell therapies | FDA | — | Agnos Therapeutics, Inc. |
tripentadecanoin | small molecules | FDA | — | SunRegen Healthcare AG |
allogeneic self-organized three-dimensional retinal tissue-sheet derived from human induced pluripotent stem cells (iPSCs) that include photoreceptor precursors | cell therapies | FDA | Sumitomo Pharma America Inc | |
a cell-based therapeutic composed of purified human rod precursor cells (hRPCs) | cell therapies | FDA | InGel Therapeutics Inc. | |
allogeneic human induced pluripotent stem cell-derived photoreceptor precursor cells | cell therapies | FDA | BlueRock Therapeutics LP | |
recombinant adeno-associated virus vector expressing ChronosFP | gene therapies | FDA | Bionic Sight, Inc. | |
N6-(3-aminopropyl)-L-lysine trihydrochloride | small molecules | FDA | — | Ren Bioscience LLC |
adeno-associated virus vector with a codon-optimized chicken Opsin 5 gene | gene therapies | FDA | — | GenAns Biotechnology Co., Ltd |
4-[[(4-Methoxyphenyl)thio]methyl]-N,N-dimethyl-1H-1,2,3-triazole-1-ethanamine | small molecules | EMA | — | Miramoon Pharma S.L. |
recombinant human adeno-associated virus serotype 2 containing PsCatCh2.0 gene | gene therapies | FDA | Zhongmou Therapeutics, Inc. | |
adeno associated virus carrying opn3 | gene therapies | FDA | — | NeoVec Biotherapeutics Inc. |
recombinant adeno-associated virus 5 vector expressing a functional human cyclic nucleotide gated channel subunit beta 1 (CNGB1) gene | gene therapies | FDA | — | National Institutes of Health National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS) |
adeno-associated virus (AAV) gene therapy product that comprised a modified AAV2 capsid and a light sensitive transgene | gene therapies | FDA | — | Skyline Therapeutics (US) Inc. |
(E)-2-((4-((4-Benzyl(ethyl)amino)phenyl)diazinyl)phenyl)amino-N,N,N-triethyl-2-oxoethan-1-aminium chloride | small molecules | EMA | Kiora Pharmaceuticals GmbH | |
Human induced pluripotent stem cells (iPSC)-derived Photoreceptor Progenitor Cells | cell therapies | FDA | — | iRegene Therapeutics Co., Ltd |
2-(4-(((4-methoxyphenyl)thio)methyl)-1H-1,2,3-triazol-1-yl)-N,N-dimethylethan-1-aminium hydrochloride | small molecules | FDA | — | Miramoon Pharma SL |
Recombinant adeno-associated virus type 5 vector containing codon optimized human RPGR^ORF15 protein coding gene (rAAV5-hRPGR^ORF15) | gene therapies | FDA | FTGEN Corp. | |
Human Retinal Pigment Epithelial Cell Injection | cell therapies | FDA | Eyecure Therapeutics Inc. | |
Adeno-associated viral vector serotype 2.NN encoding the human cyclic nucleotide-gated channel subunit A1 gene | gene therapies | FDA | ViGeneron GmbH | |
Human Nuclear Hormone Receptor Subfamily 2 Group E Member 3 (hNR2E3) | gene therapies | FDA | Ocugen, Inc. | |
adeno-associated virus serotype 8 expressing Cas9 gene and single guide RNA targeting R135W mutation in Rhodopsin gene | gene therapies | FDA | Chigenovo Co., Ltd. | |
AAV2/8-SaCas9-sgRNA RHO-T17M | gene therapies | FDA | Chigenovo Co., Ltd. | |
Adeno-associated virus serotype R100 containing the human RPGRorf15 gene isoform | gene therapies | EMA | Pharma Gateway AB | |
Benzyl ethyl aminoazobenzene quaternary ammonium | small molecules | FDA | Kiora Pharmaceuticals, Inc. | |
Methotrexate | small molecules | FDA | Aldeyra Therapeutics, Inc. | |
Melatonin | small molecules | EMA | — | Worphmed S.r.l. |
Melatonin | small molecules | FDA | — | WORPHMED Srl |
Small molecule inhibitor of kinase mediators of the Wnt pathway | small molecules | FDA | Endogena Therapeutics, Inc, | |
(+)-5-chloro-1-ethyl-3-(2-hydroxy-3-methoxybenzyl)-2-oxoindolin-3-yl dimethylcarbamate | small molecules | FDA | — | MitoChem Therapeutics, Inc. |
Adeno-associated virus serotype 5 containing the human NR2E3 gene | gene therapies | EMA | Ocugen Limited | |
Chemically induced photoreceptor-like cells | proteins | FDA | — | CiRC Biosciences, Inc. |
DNA plasmid encoding human transferrin gene | oligonucleotides | EMA | — | PulseSight Therapeutics |
DNA plasmid encoding the human transferrin gene | gene therapies | FDA | — | PulseSight Therapeutics |
Adeno-associated virus serotype 2/8 vector containing the human PDE6A gene | gene therapies | EMA | Institute For Ophthalmic Research | |
Adeno-Associated Virus containing the gene for human Nuclear Hormone Receptor NR2E3 (AAV-hNR2E3) | gene therapies | FDA | Ocugen Inc. | |
sulindac | small molecules | FDA | — | Prolindox, Inc. |
Adeno-associated viral vector serotype 8 containing cDNA of the human PDE6A protein | gene therapies | FDA | Universitätsklinikum Tübingen (UKT) | |
antisense oligonucleotide targeting the P23H mutation of the RHO gene | oligonucleotides | FDA | ProQR Therapeutics IV B.V. | |
2'-O-(2-methoxyethyl)-modified antisense oligonucleotide targeting exon 13 in the USH2A gene | oligonucleotides | EMA | Laboratoires Thea | |
Adenovirus-associated viral vector serotype 8 containing the human RPGR gene | gene therapies | EMA | Biogen Netherlands B.V. | |
2¿-O-(2-methoxyethyl) modified antisense oligonucleotide targeting exon 13 in the USH2A gene | oligonucleotides | FDA | Laboratoires Théa | |
Adeno Associated Virus carried Multi Characteristic Opsin | gene therapies | FDA | Nanoscope Therapeutics Inc. | |
Antisense oligonucleotide targeting exon 13 in the USH2A gene | oligonucleotides | EMA | ProQR Therapeutics IV BV | |
Lens epithelial derived growth factor (1-326) | proteins | EMA | — | Dorian Regulatory Affairs B.V. |
recombinant adeno-associated virus vector expressing the retinitis pigmentosa GTPase regulator | gene therapies | FDA | Beacon Therapeutics | |
antisense oligonucleotide targeting exon 13 of the USH2A gene | oligonucleotides | FDA | ProQR Therapeutics IV B.V. | |
antisense oligonucleotide targeting the c.7595-2144A>G mutation in intron 40 of the USH2A gene | oligonucleotides | FDA | ProQR Therapeutics IV B.V. | |
Antisense oligonucleotide targeting the USH2A gene | oligonucleotides | EMA | ProQR Therapeutics IV BV | |
adeno-associated viral vector serotype 2.7m8 containing the chrimsonR-tdTomato gene | gene therapies | FDA | GenSight Biologics | |
Adeno-associated viral vector serotype 8 encoding engineered rhodopsin DNA-binding repressor and human rhodopsin expression cassettes | gene therapies | EMA | — | Fondazione Telethon Ets |
adenovirus associated viral vector serotype 5 containing the RPGR gene | gene therapies | FDA | MeiraGTx, LLC | |
Adeno-associated viral vector serotype 5 containing the human RLBP1 gene | gene therapies | EMA | Coave Therapeutics | |
Adeno-associated viral vector serotype 2/2 containing a gene encoding the channelrhodopsin-2 protein [RST-001] | gene therapies | EMA | Allergan Pharmaceuticals International Limited | |
Adenovirus associated viral vector serotype 5 containing the human RPGR gene | gene therapies | EMA | MeiraGTx Belgium | |
Adeno-associated viral vector serotype 2.7m8 containing the ChrimsonR-tdTomato gene | gene therapies | EMA | GenSight- Biologics | |
adenovirus-associated viral vector serotype 5 containing the human pde6B gene | gene therapies | FDA | eyeDNA Therapeutics | |
4-((2E)-1-oxo-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-propen-1-yl)-1-piperazinecarboxamide | small molecules | EMA | — | Shire Pharmaceuticals Ireland Limited |
Recombinant adeno-associated viral vector containing the human RPGR gene | gene therapies | EMA | FGK Representative Service GmbH | |
Allogeneic fetal human retinal progenitor cells expanded ex vivo | cell therapies | EMA | Voisin Consulting Life Sciences | |
4-[(2E)-1-Oxo-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-propen-1-yl]-1-piperazinecarboxamide | small molecules | FDA | — | Shire HGT, Inc. |
Adenovirus-associated viral vector serotype 2 containing the human RPE65 gene [Luxturna] | gene therapies | EMA | Approved | Novartis Europharm Limited |
Recombinant human mesencephalic astrocyte-derived neurotrophic factor | proteins | EMA | — | Regintel Limited |
Sodium 3-[(4aR,6R,7R,7aS)-7-hydroxy-2-oxido-2-sulfanylidene-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-6-yl]-2-bromo-6-phenyl-5H-imidazo[1,2-a]purin-9-one | gene editing enzymes | EMA | — | Universitätsklinikum Tübingen (UKT) |
Myriocin | small molecules | EMA | — | Nanovector s.r.l. |
human recombinant mesencephalic, astrocyte derived neurotrophic factor | proteins | FDA | — | Amarantus BioScience Holdings, Inc. |
non-replicating recombinant adeno-associated virus vector containing a fragment of the gene encoding channelrhodopsin-2 protein | gene therapies | FDA | Allergan, Inc. | |
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid | small molecules | FDA | Celavista Mitobiogenesis, S.L. | |
recombinant lens epithelium derived growth factor 1-326 | proteins | FDA | — | Ocugen, Inc. |
N-acetyl cysteine amide | small molecules | FDA | Nacuity Pharmaceuticals, Inc. | |
expanded human allogeneic neural retinal progenitor cells extracted from neural retina | cell therapies | FDA | ReNeuron Ltd | |
recombinant human nerve growth factor | proteins | FDA | Dompe S.p.A. | |
Adenovirus associated viral vector serotype 5 containing the human pde6ß gene | gene therapies | EMA | eyeDNA Therapeutics | |
Expanded human allogeneic neural retinal progenitor cells extracted from neural retina | cell therapies | EMA | Reneuron Ireland Limited | |
Unoprostone isopropyl | small molecules | EMA | [INACTIVE] Pharmalex UK Services Limited | |
Recombinant human nerve growth factor | proteins | EMA | Dompé farmaceutici S.p.A. | |
Encapsulated human retinal pigment epithelial cell line transfected with plasmid vector expressing human ciliary neurotrophic factor | cell therapies | EMA | Le4d Global Regulatory Science Limited | |
adeno-associated viral vector containing DNA encoding an RNAi targeting rhodopsin in combination with an adeno-associated viral vector containing DNA encoding a rhodopsin gene | gene therapies | FDA | — | Spark Therapeutics Ireland Ltd. |
Adeno-associated viral vector serotype 8 encoding an inducible short hairpin RNA targeting claudin-5, Alvespimycin [AT-0002] | gene therapies | EMA | — | [INACTIVE] Alimentary Health Limited |
Adeno-associated viral vector serotype 8 encoding an inducible short hairpin RNA targeting claudin-5, Alvespimycin | small molecules | EMA | — | [INACTIVE] Alimentary Health Limited |
human retinal progenitor cells | cell therapies | FDA | jCyte, Inc. | |
Recombinant human methionine proinsulin | proteins | EMA | — | ProRetina Therapeutics S.L. |
9-cis-Retinyl acetate | small molecules | EMA | Granzer Regulatory Consulting & Services GmbH | |
Adeno-associated viral vector serotype 5 containing a rhodopsin gene [GT038] | gene therapies | EMA | — | [INACTIVE] Spark Therapeutics Ireland Limited |
zuretinol acetate | small molecules | FDA | Retinagenix LLC | |
unoprostone isopropyl | small molecules | FDA | R-Tech Ueno, Ltd. | |
Epitalon | peptides | FDA | — | BioDiem Ltd |
Recombinant human proinsulin | proteins | EMA | — | ProRetina Therapeutics S.L. |
recombinant human proinsulin (Including rhPI-Methionine) | proteins | FDA | — | ProRetina Therapeutics, S.L. |
Palucorcel [CNTO2476] | cell therapies | EMA | Janssen Biologics B.V. | |
recombinant human rod-derived cone viability factor | proteins | FDA | — | Fovea Pharmaceuticals |
Rod-derived cone viability factor, recombinant | proteins | EMA | — | [INACTIVE] Fovea Pharmaceuticals |
Adenovirus associated viral vector serotype 4 containing the human RPE65 gene | gene therapies | EMA | — | Coave Therapeutics |
4,7,10,13,16,19-docosahexaenoic acid | small molecules | EMA | — | Celavista Mito-Biogenesis S.L. |
Human umbilical tissue-derived cells | cell therapies | FDA | Janssen Research & Development, LLC | |
Urea for intravitreal injection | gene therapies | FDA | — | Vitreo Retinal Techologies, Inc |
revakinagene taroretcel | cell therapies | FDA | — | Neurotech USA, Inc. |
Gangliosides as sodium salts | small molecules | FDA | — | Fidia Pharmaceutical Corp. |
“Terminated” – programs with discontinued clinical trials, or with no updates reported for 5 years after completion or 12 years after the last trial started.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.